Stifel raised the firm’s price target on Silk Road Medical to $23 from $20 and keeps a Buy rating on the shares. The company delivered a strong Q4 sales beat, with better-than-expected performance arguing the ongoing TCAR, Transcarotid Artery Revascularization, -adoption-story is intact, the analyst tells investors.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on SILK:
- Silk Road Medical Reports Fourth Quarter and Full Year 2023 Financial Results and Provides 2024 Financial Outlook
- SILK Earnings this Week: How Will it Perform?
- Silk Road Medical participates in a conference call hosted by Lake Street
- Silk Road Medical to Report Fourth Quarter and Full Year 2023 Financial Results on February 28, 2024
- Silk Road Medical upgraded to Buy from Hold at Stifel
